HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, April 2, 2019 (Pharmacist'sd Briefing) -- In an American Heart Association scientific statement published online March 27 in Circulation, best practices are presented for diagnostic evaluation and management of myocardial infarction in the absence of obstructive coronary artery disease (MINOCA).
Jacqueline E. Tamis-Holland, M.D., from Mount Sinai St. Luke's Hospital in New York City, and colleagues provided an updated definition for MINOCA and developed a framework and algorithms for its diagnostic evaluation and management.
The authors recommend a three-step approach for diagnosis of MINOCA. The initial evaluation involves consideration of the clinical context and exclusion of overt causes for a myocardial infarction that led to diagnosis of acute myocardial infarction but on further review was not the result of an ischemic event. Clinicians should then exclude alternative conditions, including missed obstruction and myocardial injury. Additional testing should be performed to confirm the diagnosis of MINOCA, including cardiac magnetic resonance imaging. Management strategies for MINOCA should include emergency supportive care, a working diagnosis approach for evaluation of patients, cardioprotective therapies, and cause-targeted therapies. The optimal evaluation should determine the specific cause for each patient so that therapies can be targeted.
"Although our proposed algorithm attempts to improve the appropriate identification of patients with MINOCA and the underlying cause, the evaluations outlined here are neither sensitive nor specific, and until more data become available, clinical judgment and individualized care are essential," the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Read this Next
Other Trending Articles